Health Care [ 5/12 ] | Biotechnology [ 24/74 ]
NASDAQ | Common Stock
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
It has a research collaboration agreement with CRISPR Therapeutics AG.
Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 19, 25 | -0.35 Increased by +38.60% | -0.40 Increased by +12.50% |
| Nov 7, 24 | -0.39 Increased by +25.00% | -0.36 Decreased by -8.33% |
| Aug 13, 24 | -0.34 Increased by +43.33% | -0.45 Increased by +24.44% |
| May 9, 24 | -0.58 Increased by +7.94% | -0.56 Decreased by -3.57% |
| Mar 21, 24 | -0.57 Increased by +14.93% | -0.59 Increased by +3.39% |
| Nov 9, 23 | -0.52 Increased by +10.34% | -0.67 Increased by +22.39% |
| Aug 10, 23 | -0.60 Increased by +1.64% | -0.68 Increased by +11.76% |
| May 11, 23 | -0.63 Increased by +20.25% | -0.70 Increased by +10.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -25.93 M Increased by +6.55% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -28.34 M Decreased by -10.52% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -24.99 M Increased by +24.92% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -29.52 M Decreased by -8.06% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 10.54 M Increased by +N/A% | -27.75 M Increased by +21.76% | Decreased by -263.27% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -25.64 M Increased by +2.96% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -33.29 M Decreased by -20.57% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -27.32 M Decreased by -4.67% | Decreased by N/A% Decreased by N/A% |
This website uses cookies. To learn more about cookies, please see our privacy policy .